Key Highlights
- Veracyte appoints Brent Shafer and Tom Miller, Ph.D., to its board.
- Brent Shafer brings over 40 years of experience in healthcare and medical devices.
- Tom Miller, Ph.D., is a leader in AI-driven drug discovery and biotech.
- Both will contribute to Veracyte’s strategic growth in diagnostics and AI.
Source: Business Wire
Notable Quotes
- “We are thrilled to welcome Brent and Tom to our board.” — Marc Stapley, CEO at Veracyte
- “I am thrilled to join the Veracyte board to support the management team in advancing their vision.” — Brent Shafer, former CEO at Cerner
- “It’s an honor to be a part of a company with such a compelling platform.” — Tom Miller, Ph.D., CEO at Iambic Therapeutics
SoHC's Take
The addition of Brent Shafer and Tom Miller to Veracyte’s board significantly enhances the company’s expertise in both traditional healthcare solutions and cutting-edge AI technology. Their combined experience will help Veracyte further its mission to revolutionize cancer diagnostics through high-value, AI-driven insights. This strategic move positions Veracyte to advance its platform, drive innovation, and expand its leadership in the rapidly evolving diagnostics landscape.
